Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02376790 · ClinicalTrials.gov registry record · Phase 3
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 851
- Enrollment target
NCT02376790 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 851 participants.
The verdict
NCT02376790, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 851 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in adults with psoriatic arthritis.
Interventions
- DRUG Methotrexate
- DRUG Etanercept
- DRUG Placebo to Etanercept
- DRUG Placebo to Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 851 participants |
| Start Date | 2015-03-03 |
| Est. Completion | 2018-07-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02376790
The ClinicalTrials.gov registry entry for NCT02376790 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 851 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Methotrexate is the first listed.
NCT02376790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02376790 about?
NCT02376790 is a clinical study titled "Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis". The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in adults with psoriatic arthritis.
What is the current status of trial NCT02376790?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 851 participants. The study started on 2015-03-03. Estimated completion is 2018-07-06.
What interventions are being tested in trial NCT02376790?
The interventions under investigation include: Methotrexate (DRUG), Etanercept (DRUG), Placebo to Etanercept (DRUG), Placebo to Methotrexate (DRUG).
Who is sponsoring clinical trial NCT02376790?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.